Results 251 to 260 of about 590,194 (288)
Some of the next articles are maybe not open access.
Bioanalysis of Meningococcal Vaccines
Bioanalysis, 2010Meningococcal meningitis is feared because of the rapid onset of severe disease from mild symptoms and, therefore, is an important target for vaccine research. Five serogroups, defined by the structures of their capsular polysaccharides, are responsible for the vast majority of disease.
Jun X. Wheeler +2 more
openaire +3 more sources
Current Pharmaceutical Design, 2007
Neisseria meningitidis is a major world-wide cause of meningitis. N. meningitidis related diseases have become more pronounced in the last decade and changes in meningococcal-associated disease have opened new opportunities for prevention and vaccine development. Although multivalent vaccines have been developed against the N. meningitidis serogroups A,
openaire +2 more sources
Neisseria meningitidis is a major world-wide cause of meningitis. N. meningitidis related diseases have become more pronounced in the last decade and changes in meningococcal-associated disease have opened new opportunities for prevention and vaccine development. Although multivalent vaccines have been developed against the N. meningitidis serogroups A,
openaire +2 more sources
Meningococcal carriage, meningococcal disease and vaccination
Journal of Infection, 1988Group A meningococcal carriage rates were determined 6 months before and 6 and 18 months after a mass vaccination campaign with a combined group A and group C meningococcal polysaccharide vaccine in a rural area of The Gambia. During the first pre-vaccination survey, performed during an outbreak of meningococcal disease, the carriage rate was high (16%)
R.A. Wall +2 more
openaire +3 more sources
The Future of Meningococcal Vaccines
Pediatric Infectious Disease Journal, 2005Despite antibiotics and supportive care ~10% of persons with meningococcal infection die 9-19% have sequelae (skin grafting amputation hearing deficits) and outbreaks often provoke panic. Meningococcal meningitis is the main cause of bacterial meningitis in children in the United States.
Carol J. Baker, C. Mary Healy
openaire +3 more sources
Recommendations for Serogroup B Meningococcal Vaccine for Persons 10 Years and Older
Pediatrics, 2016This policy statement provides recommendations for the prevention of serogroup B meningococcal disease through the use of 2 newly licensed serogroup B meningococcal vaccines: MenB-FHbp (Trumenba; Wyeth Pharmaceuticals, a subsidiary of Pfizer ...
C. Byington +31 more
semanticscholar +1 more source
Meningococcal conjugate vaccines
Expert Opinion on Biological Therapy, 2005Disease caused by Neisseria meningitidis is associated with high mortality rates and significant sequelae. Polysaccharide meningococcal vaccines have been available for > 20 years, and have been used in travellers to control outbreaks, and in some countries for adolescents entering college, although they provide only a short duration of immunity and do
openaire +3 more sources
Expert Review of Vaccines, 2018
Introduction: Given the characteristics of meningococcal carriage and transmission and the sudden, often severe onset and long-term consequences of disease, vaccination can most effectively provide large-scale control of invasive disease. Six serogroups (
John L. Perez +12 more
semanticscholar +1 more source
Introduction: Given the characteristics of meningococcal carriage and transmission and the sudden, often severe onset and long-term consequences of disease, vaccination can most effectively provide large-scale control of invasive disease. Six serogroups (
John L. Perez +12 more
semanticscholar +1 more source
Meningococcal vaccine in travelers
Current Opinion in Infectious Diseases, 2007New vaccines to prevent meningococcal disease have been licensed in recent years. It is therefore timely to discuss current vaccine strategies pertinent to international travelers in relation to the changing epidemiology.Serogroup W135 achieved epidemic status in Africa in 2002, and then largely disappeared over a short time period. The year 2006 saw a
openaire +2 more sources
A half-century of meningococcal vaccines
Vaccine, 2021The first safe and effective vaccine for the prevention of invasive meningococcal disease was created fifty years ago. The vaccine employed a novel platform, polysaccharide capsular antigen, based on the discovery that anticapsular antibody conferred protective immunity in humans.
openaire +3 more sources
The Future of Meningococcal Vaccines
Pediatric Health, 2007The use of vaccines in the prevention of meningococcal disease has demonstrated their success in improving public health globally. Group C conjugate vaccines have significantly reduced the burden of disease in countries with widespread usage. Promising results are available on the candidate group A conjugate vaccine for Africa, which could potentially ...
Paul Balmer, Ray Borrow
openaire +2 more sources